Skip to content
PTCTPTC Therapeutics, Inc.

Earnings

When PTC Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

59 quarters. Mar 31, 2012 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 18, after the close

Thu, Feb 18, 2027in 92 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 18 – Mar 4

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$164.68M
Revenue, change from a year earlier: Q3 2026 +69.6%, Q2 2026 +101.5%, Q1 2026 −76.8%, Q4 2025 −22.7%
Net income
-$134.97M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$357.81M+69.6% vs Q3 2025

Latest results

  1. Q3 2026Oct 29, 2026, after the closeThe release7.1%by the close of Oct 30
    Revenue
    $357.81M
    +69.6%
    Net income
    -$51.69M
    N/M
    EPS
    -$0.62
    N/M
    Total net product revenue and royalty revenue was $357.6 million for the third quarter of 2026, compared to $201.7 million for the third quarter of 2025.
  2. Q2 2026Jul 30, 2026, after the closeThe release10.1%by the close of Jul 31
    Revenue
    $360.52M
    +101.5%
    Net income
    $83.50M
    N/M
    EPS
    $0.92
    N/M
  3. Q1 2026May 7, 2026, after the closeThe release+14.3%by the close of May 8
    Revenue
    $272.55M
    −76.8%
    Net income
    -$2.81M
    N/M
    EPS
    -$0.03
    N/M
  4. Q4 2025Feb 19, 2026, after the closeThe release+1.0%by the close of Feb 20
    Revenue
    $164.68M
    −22.7%
    Net income
    -$134.97M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Oct 29, 2026 · after-hoursOct 29, 202629 d10-Q$357.81M+69.6%-$0.627.1%
Q2 2026Jun 30, 2026Jul 30, 2026 · after-hoursJul 30, 202630 d10-Q$360.52M+101.5%$0.9210.1%
Q1 2026Mar 31, 2026May 7, 2026 · after-hoursMay 7, 202637 d10-Q$272.55M−76.8%-$0.03+14.3%
FY 2025
Q4 2025derivedDec 31, 2025Feb 19, 2026 · after-hoursFeb 19, 202650 d10-K$164.68M−22.7%—+1.0%
Q3 2025Sep 30, 2025Nov 4, 2025 · after-hoursNov 4, 202535 d10-Q$211.01M+7.2%$0.20+5.8%
Q2 2025Jun 30, 2025Aug 7, 2025 · after-hoursAug 7, 202538 d10-Q$178.88M−4.2%-$0.839.8%
Q1 2025Mar 31, 2025May 6, 2025 · after-hoursMay 6, 202536 d10-Q$1.18B+459.7%$10.04+12.5%
FY 2024
Q4 2024derivedDec 31, 2024Feb 27, 2025 · after-hoursFeb 27, 202558 d10-K$213.17M−30.6%—+9.3%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 7, 202438 d10-Q$196.79M+0.1%-$1.39+2.9%
Q2 2024Jun 30, 2024Aug 8, 2024 · after-hoursAug 8, 202439 d10-Q$186.70M−12.7%-$1.29—
Q1 2024Mar 31, 2024Apr 25, 2024 · after-hoursApr 25, 202425 d10-Q$210.12M−4.7%-$1.20+10.0%
Earlier years, FY 2012 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QOct 29, 2026120223
10-QJul 30, 2026000017
10-QMay 7, 2026000012
10-KFeb 19, 2026017575
10-QNov 4, 2025000028
10-QAug 7, 2025010796
10-QMay 6, 2025000019
10-KFeb 27, 2025000012
10-QNov 7, 2024000023
10-QAug 8, 2024000017

Provenance

ProvenanceData status and checks

PTC Therapeutics, Inc. · CIK 1070081 · Engraved from SEC EDGAR